Search

Displaying results 2281 - 2290 of 4300 in total
  1. Drug

    Ephedra sinica root

    go.drugbank.com/drugs/DB01363
    ApprovedNutraceutical

    Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 d...

  2. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function

  3. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  4. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Desmoid tumors are typically characterized by aberrant activation in Notch signaling. … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling

  5. Drug

    Pivampicillin

    go.drugbank.com/drugs/DB01604
    ApprovedWithdrawn

    Pivalate ester analog of ampicillin.

  6. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    protecting against destruction of host cells mediated by the toxin. … Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin[A191829, L31568, L31573] and thereby preserving human immune cells by

  7. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.

  8. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  9. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenou...

  10. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.